Teva Pharmaceutical Industries has reached an agreement in principle to settle a lawsuit over alleged generic drug price-fixing. The suit was brought by 45 U.S. states. Washington, D.C., and two U.S. territories also joined the case. A federal judge in Connecticut put the case on hold following the agreement.
The states alleged that Teva and other drugmakers began conspiring in 2012 to maintain market share while raising prices on generic medications. The alleged scheme involved as many as 112 drugs. Some price increases exceeded 1,000%.
The financial terms of the settlement in principle have not been disclosed. It addresses the states’ civil claims and is separate from a 2023 deferred prosecution agreement Teva reached with the U.S. Department of Justice to resolve criminal charges.